Status:
UNKNOWN
IFN Beta-1b and Ribavirin for Covid-19
Lead Sponsor:
The University of Hong Kong
Collaborating Sponsors:
Hospital Authority, Hong Kong
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
As of 1 July 2020, more than 10 million people been confirmed to have infected by SARS-CoV-2, resulting in more than 500,000 deaths. No specific antiviral treatment for the SARS-CoV-2 is currently ava...
Detailed Description
The novel coronavirus (SARS-CoV-2), is a single-stranded RNA coronavirus. The virus was first isolated from patients presented with pneumonia in Wuhan in December 2019. It is believed that the virus f...
Eligibility Criteria
Inclusion
- Recruited subjects include all adult patients ≥18 years hospitalized for virologic confirmed SARS-CoV-2 infection.
- All subjects give written informed consent. For patients who are critically ill, requiring ICU, ventilation or confused, informed consent will be obtained from spouse, next-of-kin or legal guardians.
- Subjects must be available to complete the study and comply with study procedures. Willingness to allow for serum samples to be stored beyond the study period, for potential additional future testing to better characterize immune response.
Exclusion
- Inability to comprehend and to follow all required study procedures.
- Allergy or severe reactions to the study drugs
- Patients taking medication that will potentially interact with l interferon beta-1b or ribavirin
- Pregnant or lactation women
- Patients with known history of severe depression
- Received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to recruitment in this study or expect to receive an experimental agent during this study.
- To participate in an unrelated trial during the current clinical trial. Nevertheless, the patients have the right to withdraw from the current clinical trial to join another clinical trial.
- Have a history of alcohol or drug abuse in the last 5 years.
- Have any condition that the investigator believes may interfere with successful completion of the study.
Key Trial Info
Start Date :
July 29 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2022
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT04494399
Start Date
July 29 2020
End Date
August 1 2022
Last Update
July 31 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Hong Kong, Queen Mary Hospital
Hong Kong, Hong Kong, 852